ArticleInternal medicine (Tokyo, Japan)2019

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.

Misato Ogata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.